This page ranks neurodegenerative diseases by various criteria including research activity, clinical trial count, therapeutic development, and knowledge base coverage in NeuroWiki. [1]
| Rank | Disease | Research Activity | Clinical Trials |
|---|---|---|---|
| 1 | Alzheimer's Disease | Very High | 200+ |
| 2 | Parkinson's Disease | Very High | 150+ |
| 3 | ALS | High | 100+ |
| 4 | Frontotemporal Dementia | High | 50+ |
| 5 | Huntington's Disease | Moderate-High | 40+ |
| 6 | Multiple System Atrophy | Moderate | 20+ |
| 7 | Progressive Supranuclear Palsy | Moderate | 15+ |
| 8 | Lewy Body Dementia | Moderate | 20+ |
| 9 | Corticobasal Degeneration | Low-Moderate | 10+ |
| 10 | Vascular Dementia | Moderate | 15+ |
| Rank | Disease | Page Count | Content Depth |
|---|---|---|---|
| 1 | Alzheimer's Disease | 150+ | Comprehensive |
| 2 | Parkinson's Disease | 120+ | Comprehensive |
| 3 | ALS | 80+ | Detailed |
| 4 | Huntington's Disease | 60+ | Detailed |
| 5 | FTD | 50+ | Detailed |
| 6 | MSA | 30+ | Moderate |
| 7 | PSP | 25+ | Moderate |
| 8 | CBD | 20+ | Moderate |
| 9 | LBD | 15+ | Moderate |
| 10 | VaD | 10+ | Basic |
| Rank | Disease | Approved Treatments | Pipeline Candidates |
|---|---|---|---|
| 1 | Alzheimer's Disease | 7 | 100+ |
| 2 | Parkinson's Disease | 20+ | 80+ |
| 3 | ALS | 3 | 60+ |
| 4 | Huntington's Disease | 1 | 40+ |
| 5 | FTD | 0 | 30+ |
| 6 | MSA | 0 | 15+ |
| 7 | PSP | 0 | 12+ |
| 8 | CBD | 0 | 10+ |
| 9 | LBD | 3 | 10+ |
| 10 | VaD | 2 | 8+ |
Diseases characterized by tau protein pathology:
Diseases characterized by alpha-synuclein pathology:
Diseases characterized by TDP-43 pathology:
Alzheimer's Disease dominates research activity with over 200 active clinical trials and the largest therapeutic pipeline. The approval of lecanemab and donanemab represents a milestone in disease-modifying therapy development.
Parkinson's Disease has the highest number of approved treatments (20+) but remains without disease-modifying therapies. Focus is on alpha-synuclein targeting and neuroprotection.
ALS has seen recent momentum with FDA approvals (AMX0035, tofersen) but remains critically undertreated. Genetic understanding (C9orf72, SOD1, FUS) is driving targeted therapy development.
These ranked items have limited content and would benefit from expansion: